Vaccine Therapy in Treating Patients With Recurrent B-Cell Lymphoma
NCT00561756 is a phase 1 interventional trial sponsored by Memorial Sloan Kettering Cancer Center. As of 21 Nov 2026, it is completed. It studies Plasmid DNA vaccine therapy in Lymphoma. The registry lists an enrollment of 8 participants at 1 site in 1 country. The registry lists a start date of 31 Oct 2007 and a primary completion date of 30 Nov 2015. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT00561756 |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional trial |
| Lead sponsor | Memorial Sloan Kettering Cancer Center |
| Enrollment | 8 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Lymphoma |
| Drugs | Plasmid DNA vaccine therapy |
| Start | 31 Oct 2007 |
| Primary completion | 30 Nov 2015 |
| Study completion | 30 Nov 2015 |
| Last update posted | 17 Nov 2015 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Alan N. Houghton, MD
Memorial Sloan Kettering Cancer Center
Principal Investigator - Andrew D. Zelenetz, MD, PhD
Memorial Sloan Kettering Cancer Center
Principal InvestigatorKOL profile → - M. Lia Palomba, MD
Memorial Sloan Kettering Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Memorial Sloan-Kettering Cancer Center
New York
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT00561756
Each answer restates registry values shown on this page.
What is NCT00561756?
NCT00561756 is a phase 1 interventional trial sponsored by Memorial Sloan Kettering Cancer Center. It studies Plasmid DNA vaccine therapy in Lymphoma.
Who leads NCT00561756?
The registry names Alan N. Houghton, MD (principal investigator, Memorial Sloan Kettering Cancer Center), Andrew D. Zelenetz, MD, PhD (principal investigator, Memorial Sloan Kettering Cancer Center) and M. Lia Palomba, MD (principal investigator, Memorial Sloan Kettering Cancer Center) as overall officials.
Where does NCT00561756 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT00561756 study?
The registered drug and biological interventions are Plasmid DNA vaccine therapy.
When did NCT00561756 end?
The registry lists a primary completion date of 30 Nov 2015 and a study completion date of 30 Nov 2015. The sponsor last updated the record on 17 Nov 2015.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.